CoolSculpting® More Accessible To Patients Through New Financing Agreement With CareCredit

ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ) – the medical technology company that developed CoolSculpting, a non-surgical, clinically proven procedure designed to selectively eliminate diet and exercise resistant fat using a patented cooling technology – today announced a new agreement with CareCredit, a leading healthcare credit card, to provide payment options to patients.

Launched nationwide, the new agreement will provide ZELTIQ’s network of more than 400 physicians the opportunity to offer their patients special financing. Even if patients have the funds available, CareCredit provides payment options for patients to build cosmetic procedures such as CoolSculpting into their monthly budget.

“Although CoolSculpting is thought to be attractively priced by consumers we speak with, this program provides payment options that patients have requested,” said Mark Foley, Interim President and Chief Executive Officer of ZELTIQ. “Thanks to this strong relationship with CareCredit, CoolSculpting will further expand the aesthetic category by providing those considering treatment with more choices on how to budget and benefit from our differentiated procedure.”

“CareCredit is a healthcare credit card that provides patients with a revolving line of credit, specifically for elective procedures like CoolSculpting,” said Tony Seymour, Senior Vice President, Sales, CareCredit. “For over 25 years, we have provided payment options that patients value and enable them to get the care they want and need for themselves and their family members. We look forward to working with CoolSculpting practices and their patients.”

CareCredit is currently accepted by over 150,000 providers. Patients can apply for CareCredit in the CoolSculpting provider’s office, online at, or via their mobile devices with the SmartPhone enabled application app. Cardholders and providers consistently share feedback about CareCredit’s value and ease-of-use. Results from regular surveys* of more than 1,500 cardholders confirm: more than 96 percent of cardholders say they are highly satisfied with the program and that the service meets or exceeds their expectations; more than 95 percent of both cardholders and providers consistently rate it a fair to excellent value; and more than 86 percent indicate they would recommend to a friend.

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value